Tandem Diabetes Care (NSDQ:TNDM) shareholders have approved a 1-for-10 reverse stock split, the company said earlier this week, which took effect today.
In a statement filed with the SEC in July, the San Diego, Calif.-based company told shareholders that it believed a reverse stock split would help Tandem keep its common stock listed on the Nasdaq market and make its stock more attractive to institutional investors.
Get the full story at our sister site, Drug Delivery Business News.
The post Tandem shareholders approve 1-for-10 reverse split appeared first on MassDevice.
from MassDevice http://ift.tt/2xvBqkj
Cap comentari:
Publica un comentari a l'entrada